Revive Therapeutics Appoints Dr. Ram Subramanian, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 08/15/17 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that Dr. Ram Subramanian, M.D., will join the Company as a Scientific Advisor for cannabinoid-based therapeutics targeting liver diseases.
"I am pleased that Dr. Subramanian has joined Revive to assist with advancing the research and clinical development of our cannabinoid-based research initiatives targeting liver diseases," said Craig Leon, Chief Executive Officer of Revive. "Dr. Subramanian will be instrumental in guiding our research and clinical development initiatives in the field of liver disease."
"I look forward to working with Revive in their objective of advancing novel cannabinoid-based therapeutic opportunities that address the unmet medical needs in liver diseases," said Dr. Ram Subramanian.
Dr. Ram Subramanian, M.D., is Associate Professor of Medicine and Surgery, and the Medical Director of Liver Transplantation at Emory Hospital and School of Medicine. In his dual role as a transplant hepatologist and an intensivist, Dr. Subramanian has a specific interest in the inpatient care of patients before and after liver transplantation. Dr. Subramanian specializes in gastroenterology, transplant hepatology, pulmonary medicine and critical care. Dr. Subramanian is an active clinician and his areas of interest include cirrhosis, critical care medicine, liver disease, and liver transplant evaluation. Dr. Subramanian''s medical education and residency training were completed at the University of Chicago. He completed a hepatology fellowship at the University of Nebraska before returning to the University of Chicago for postgraduate training leading in gastroenterology, pulmonology, and intensive care. He is board certified by the American Board of Internal Medicine in Internal Medicine, Gastroenterology, Transplant Hepatology, Critical Care Medicine and Pulmonary Medicine.
About Revive Therapeutics Ltd.
Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) is focused on the research, development and commercialization of novel treatments for serious and unmet medical needs by identifying and investigating potential drugs and plant-based therapies, such as cannabinoids, that may be repurposed for new indications, be delivered in a different way, combined with existing drugs, or be developed as new chemical entities or prodrugs. Additional information on Revive is available at .
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This news release includes certain information and statements about management''s view of future events, expectations, plans and prospects that constitute "forward-looking statements", which are not comprised of historical facts. Forward-looking statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could", "would", "will", or "plan", and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the joint venture with InMed Pharmaceuticals Inc. for development of cannabinoid-based therapies for targeting kidney diseases and entering into a definitive joint venture agreement; the granting of a patent for Bucillamine for the treatment of gout; the potential efficacy and commercial viability of Bucillamine for treatment of gout and Bucillamine for the treatment of Cystinuria; expansion of the Bucillamine clinical testing program; the Company''s drug research and development, and commercialization plans; the Company''s research, development and commercialization plans for plant-based therapies, including cannabinoids; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those anticipated or implied in such forward-looking statements. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management''s expectations. In formulating the forward-looking statements contained herein, management has assumed: that business and economic conditions affecting Revive will continue substantially in the ordinary course and will be favourable to Revive; that clinical testing results will justify commercialization of the Company''s drug candidates; that Revive will be able to obtain all requisite regulatory approvals to commercialize its drug candidates; that such approvals will be received on a timely basis; and, that Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect.
Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: the inability to conclude a joint venture with InMed Pharmaceuticals Inc. on terms which are commercially reasonable or at all; uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the Company''s ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Revive''s Management''s Discussion & Analysis for the period ended June 30, 2016 and Revive''s other public filings, all of which may be viewed on SEDAR (). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Craig Leon
Chief Executive Officer
Revive Therapeutics Ltd.
(416) 272-5525
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.08.2017 - 05:00 Uhr
Sprache: Deutsch
News-ID 1517537
Anzahl Zeichen: 3039
contact information:
Contact person:
Town:
TORONTO, ONTARIO
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 345 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Revive Therapeutics Appoints Dr. Ram Subramanian, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases
"
steht unter der journalistisch-redaktionellen Verantwortung von
Revive Therapeutics Ltd. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
